JCI:NK cell-assisted PD-1 is used in NSCLC, and the effect is multiplied.

The new study, conducted by Professor Jiang Yong of the Key Proteomics Laboratory in Guangdong Province, found that PD-1 inhibitors were active in clinical treatment for non-small cell lung cancer, and found that in addition to T cells, NK cells not only express PD-L1 proteins, but also have the potential to prolong the survival of patients with advanced non-small cell lung cancer.
1. The tumor reaction was assessed objectively by radiology and judged according to the solid tumor mitigation assessment criteria (RECIST) guidelines, the ORR of the selected patients was 27.5%, and the ORR of Group A was 36.5%, which was significantly better than the 18.5% of Group B.
showed that The therapeutic effect of Pym monoantial combination NK cell therapy was nearly 1 times that of Pym monoantial therapy alone.
, the maximum transverse diameter (MTD) of the tumor was significantly reduced in Group A patients treated with Pym monoant anti-combined NK cells.
group A lymphocytes, especially NK cells, increased significantly after the combined treatment of 2 and immunodeficiration parameters (Figure A).
treatment, the absolute number of total T-cells, CD8-plus T-cells, CD4-T cells, and NK cells per microlitre was 811.4, 420.1, 315.0, and 66.1, respectively.
treatment, the absolute number of the same subsystres per microlitre of lymphocytes increased to 1115.7, 569.2, 444.5 and 125.6, respectively.
notable, after the combined treatment, NK cells increased from 8.76 percent to 20.67 percent to 5.31 percent of the total cell population.
interestingly, there was a significant increase in the levels of Group A Th1 cytokines (including IL-2, TNF-beta and IFN-cytokines, mainly to enhance the anti-infection immunity mediated by phagocytosis, especially infections of intracellular pathogens) after treatment (Figure B).
3, tumor markers, circulating tumor cells Although the fact that Pym monotherapy was found to have some effect in Group B, the levels of cancer embryo antigen (CEA), cytochroprotein 19 antigen 21-1 (Cyfra21-1) or carbohydrate antigen 125 (CA125) in Group A were significantly reduced after the combined treatment (Figure C).
The combined treatment in Group A had a more significant effect on the reduction of circulating tumor cells (CTC) in the blood in group A (13.0 to 5.3 before treatment and 10.8 to 3.1, P.lt;0.05) (Figure D) compared to the Pym monotherapy option in Group B.
, the average total survival (OS) of patients in Group A was 15.5 months (Figure A), longer than in Group B patients.
the benefits of group A patients receiving combined treatment were consistently observed in all subgroups analysed (Figure B).
in patients with a PD-L1 Tumor Ratio Score (TPS) of 50% or higher, the medium OS in Group A patients was 17.0 months, longer than the medium OS in Group B patients (Figure C).
addition, the mesoos of patients receiving multi-course NK cell infusions were significantly longer than those receiving only one-course NK cell infusions (Figure D).
5, non-progressed survival group A patients with a medium progressity-free lifetime (PFS) of 6.5 months (Figure A), better than patients in group B.
in all subgroups analysed, the benefits of group A patients receiving combined treatment were consistently observed (Figure B).
PFS was 7.0 months for patients in Group A with PD-L1 TPS of 50% or higher, longer than in the corresponding Group B patients (Figure C).
, however, the study failed to detect a mid-level PFS difference between patients who received a single NK cell infusion and those who received multiple NK cell infusions (Figure D).
6, safety in addition, throughout the trial process, treatment tolerance is good.
previous trials by researchers confirmed that NK cell infusions had no serious side effects, so adverse reactions should be attributed to Pym monoantia, but adverse events could be controlled and all symptoms were alleviated after treatment.
source: !-- content presentation ends -- !-- to determine whether the login ends.